Below are three grant opportunities in amyloid that may of particular interest to our ASE members involved in research and quality initiatives. Please see below for more details on these opportunities from Pfizer.
“Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and notes who will make final grant decisions. Organizations are invited to submit an application addressing the gaps as outlined in the RFP.
For all independent medical grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent program.
Please scroll down to find information on the following three RFPs:
- Quality Improvement Grants to Support Development of Cardiac Amyloid Centers
- Transthyretin Cardiac Amyloidosis Fellowship
- Local Level Educational Grants Program to Increase Awareness & Understanding of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Refer to complete details in the full RFP documents. If you have questions regarding these RFPs, please direct them in writing to Amanda Stein, Grant Officer (amanda.j.stein@pfizer.com).
1. Request for Proposals (RFP): Quality Improvement Grants to Support Development of Cardiac Amyloid Centers
Date RFP Issued: February 8, 2021
Geographic Scope: United States
Clinical Area: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Link to full RFP: Quality Improvement Grants to Support Development of Cardiac Amyloid Centers
Application Due Date: April 8, 2021
Specific Area of Interest: Projects that will be considered for Pfizer support will focus on supporting the development of cardiac amyloid centers that provide leadership, best practices, support and/or training of HCPs within a multidisciplinary team environment in order to improve the quality of care for cardiac amyloidosis patients.
2. Request for Proposals (RFP): Transthyretin Cardiac Amyloidosis Fellowship
Date RFP Issued: February 8, 2021
Geographic Scope: United States
Clinical Area: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Link to full RFP: Transthyretin Cardiac Amyloidosis Fellowship
Application Due Date: June 15, 2021
Specific Area of Interest: It is our intent to support institutions with fellowship programs for Cardiologists that have a strong focus on clinical practice, research, and education to further the understanding of transthyretin cardiac amyloidosis.
3. Request for Proposals (RFP): Local Level Educational Grants Program to Increase Awareness & Understanding of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Date RFP Issued: February 8, 2021
Geographic Scope: United States
Clinical Area: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Link to full RFP: Local Level Educational Grants Program to Increase Awareness & Understanding of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Application Due Date: 2021 application windows – please see RFP for details
Specific Area of Interest: Projects that will be considered for Pfizer support will include local/community activities that focus on improving the care of patients by:
- Educating [HCPs] to increase awareness and enable appropriate patient identification by closing knowledge gaps in disease epidemiology, pathophysiology, diagnosis, and emerging treatment paradigms.
- Addressing barriers to appropriate diagnosis and strategies that reduce burdens for patients and providers along the pathway to appropriate diagnosis
- Exploring strategies that empower patients to play an active role in understanding TTR amyloidosis and decision making regarding available diagnostic and treatment options
- Increasing awareness of the changing epidemiology of TTR amyloidosis with a focus on the prevalence of hereditary ATTR and wild-type ATTR subtypes as the science continues to evolve
- Increasing awareness of at risk and undiagnosed populations with TTR amyloidosis with a focus on improving strategies that facilitate the appropriate diagnosis of patients early in the disease course before overt cardiomyopathy has ensued [e.g. populations with electrical disturbances, valvular disease, orthopedic manifestations, and cardio-oncology diseases (i.e. Light Chain Amyloidosis)]
- Increasing awareness of bone radiotracer scintigraphy as a non-invasive alternative to invasive endomyocardial biopsy for the appropriate diagnosis of TTR cardiac amyloidosis in select patients
- Supporting the dissemination of information related to the pharmacologic and non-pharmacologic management of ATTR-CM
- Addressing geographic and racial healthcare disparities
- Addressing challenges to appropriate diagnoses and caring for patients during an era of increased telehealth utilization
- Supporting the development of cardiac amyloid centers that provide leadership, best practices, support and/or training of HCPs within a multidisciplinary team environment in order to improve the quality of care for cardiac amyloidosis patients.”